Advertisement
Advertisement
YARW
Yarrow Bioscience, Inc. Common Stock
20.00
USDSponsored
+0.43
+2.20%
Oct 29, 15:59 UTC -4
Closed
Pre-Market
20.00
0.00
+0.02%
Yarrow Bioscience, Inc. Common Stock (YARW) Earnings
YARW Earnings Reports
Positive Surprise Ratio
YARW beat 1 of 1 last estimates.
100%
Next Report
Next Week
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$204.00K
/-$0.32
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-96.24%
Yarrow Bioscience, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, YARW reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.18 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 204.00 thousand, with a --% difference.
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.32 USD, with revenue projected to reach 204.00 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
Gilead Sciences Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.24
Actual
$2.54
Surprise
+13.66%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
FAQ
What were Yarrow Bioscience, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Yarrow Bioscience, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Yarrow Bioscience, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Yarrow Bioscience, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Yarrow Bioscience, Inc. Common Stock's next earnings report?
Based on --
analysts, Yarrow Bioscience, Inc. Common Stock is expected to report EPS of -$0.32 and revenue of $204.00K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.